Endo names Campanelli president, CEO

DUBLIN — Endo has a new president and CEO. The company announced Tuesday that its board of directors had named Paul Campanelli to the position, effective immediately, succeeding Ravid De Silva, who has stepped down from the position and his place on the company's board of directors.

 

“I am very excited to lead Endo at this important time and, together with a strong senior management team, address the challenges of today's healthcare environment,” Campanelli said.  “I look forward to working closely and collaboratively with our leadership team and Endo's Board to build on our strengths and help position the company to thrive over the long-term.”

 

Campanelli takes the reigns at Endo from his position as president of its generic and OTC business Par Pharmaceutical, which makes up about 60% of Endo’s total revenue. He had been Par’s CEO from 2012 until the company was acquired by Endo in 2015. During his time at the head of Par, the company grew its total revenue, acquired JHP Pharmaceuticals and established itself in the European generics market. 

 

“Given the continued evolution of Endo's business and Paul's impressive track record of delivering strong operating results, the Board concluded that Paul is the right leader for Endo at this juncture as we focus on execution and increasing the value of our attractive U.S. Branded, U.S. Generic and International pharmaceutical assets,” Endo board chairman Roger Kimmel said. “The Board believes his experience positions him to drive a broad range of growth initiatives across Endo's entire portfolio, generating better health outcomes for patients and creating value for Endo's shareholders.”

 

Alongside the announcement, Endo affirmed its guidance for the third quarter and full-year, expecting Q3 revenues between $830 million and $870 million and full-year revenues of between $3.87 billion and $4.03 billion.